Moderna's mRNA-1083, a combined flu and COVID-19 vaccine, has been authorized for use in Europe, marking the first approval globally. This development highlights Europe’s proactive stance on innovative vaccines, potentially setting a precedent for future regulatory approaches in biotech. Developers should watch how this impacts US regulatory timelines for similar innovations.
Read the full article at Ars Technica
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



